Treatment of Depression with Botulinum Toxin A: A Case Series

    loading  Checking for direct PDF access through Ovid



Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches.


To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial.


Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II.


Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood.


To our knowledge, these are the first reported cases of depression treated with botulinum toxin A.

Related Topics

    loading  Loading Related Articles